Ana Alfonso Alfonso-Piérola

Dr. Ana Alfonso Alfonso-Piérola

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022 in Science Advances
Verified
Journal Article
Open access
PRPaula Rodriguez-Marquez
Paula Rodriguez-Marquez
MCMaria E. Calleja-Cervantes
Maria E. Calleja-Cervantes
GSGuillermo Serrano
Guillermo Serrano
AOAina Oliver-Caldes
Aina Oliver-Caldes
MPMaria L. Palacios-Berraquero
Maria L. Palacios-Berraquero
FPFelipe Prosper
Felipe Prosper
Identification of new markers associated with long-term efficacy in patients treated with CAR T cells is a current medical need, particularly in diseases such as multiple myeloma. In this study, we address the impact of CAR density on the functionality of BCMA CAR T cells. Functional and transcriptional studies demonstrate that CAR T cells with high expression of the CAR construct show an increased tonic signaling with up-regulation of exhaustion markers and increased in vitro cytotoxicity but a decrease in in vivo BM infiltration. Characterization of gene regulatory networks using scRNA-seq identified regulons associated to activation and exhaustion up-regulated in CAR High T cells, providing mechanistic insights behind differential functionality of these cells. Last, we demonstrate that patients treated with CAR T cell products enriched in CAR High T cells show a significantly worse clinical response in several hematological malignancies. In summary, our work demonstrates that CAR density plays an important role in CAR T activity with notable impact on clinical response.

1 January 2013 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
AAAna Alfonso Alfonso-Piérola
Ana Alfonso Alfonso-Piérola
DJDavid Jiménez
David Jiménez
CCCarmen Fernández Capitán
Carmen Fernández Capitán
PPPaolo Prandoni
Paolo Prandoni
PWPhilip S. Wells
Philip S. Wells
TIthe RIETE Investigators
the RIETE Investigators
Summary: In patients with venous thromboembolism (VTE), assessment of the risk of fatal recurrent VTE and fatal bleeding during anticoagulation may help to guide intensity and duration of therapy. We aimed to provide estimates of the case-fatality rate (CFR) of recurrent VTE and major bleeding during anticoagulation in a ‘real life’ population, and to assess these outcomes according to the initial presentation of VTE and its etiology. The study included 41,826 patients with confirmed VTE from the RIETE registry who received different durations of anticoagulation (mean 7.8 ± 0.6 months). During 27,110 patient-years, the CFR was 12.1% (95% CI, 10.2–14.2) for recurrent VTE, and 19.7% (95% CI, 17.4–22.1) for major bleeding. During the first three months of anticoagulant therapy, the CFR of recurrent VTE was 16.1% (95% CI, 13.6–18.9), compared to 2.0% (95% CI, 0–4.2) beyond this period. The CFR of bleeding was 20.2% (95% CI, 17.5–23.1) during the first three months, compared to 18.2% (95% CI, 14.0–23.2) beyond this period. The CFR of recurrent VTE was higher in patients initially presenting with PE (18.5%; 95% CI, 15.3–22.1) than in those with DVT (6.3%; 95% CI, 4.5–8.6), and in patients with provoked VTE (16.3%; 95% CI, 13.6–19.4) than in those with unprovoked VTE (5.5%; 95% CI, 3.5–8.0). In conclusion, the CFR of recurrent VTE decreased over time during anticoagulation, while the CFR of major bleeding remained stable. The CFR of recurrent VTE was higher in patients initially presenting with PE and in those with provoked VTE.

28 March 2017 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
AAAna Alfonso Alfonso-Piérola
Ana Alfonso Alfonso-Piérola
GMGuillermo Montalban‐Bravo
Guillermo Montalban‐Bravo
KTKoichi Takahashi
Koichi Takahashi
EJElias Jabbour
Elias Jabbour
TKTapan Kadia
Tapan Kadia
GGGuillermo Garcia‐Manero
Guillermo Garcia‐Manero
Hypomethylating agents (HMA) are the most commonly used therapeutic intervention in chronic myelomonocytic leukemia (CMML). Due to the lack of CMML‐specific clinical trials, the impact of these agents in the natural history of CMML is not fully understood. We present the largest retrospective series of CMML (n = 151) treated with HMA. Mean age at diagnosis was 69 years (range 50‐88). According to the CMML‐specific prognostic scoring system (CPSS): 17 (15%) were low‐risk, 45 (39%) intermediate‐1 risk, 42 (36%) intermediate‐2, and 12 (10%) high‐risk. 35 (23%) patients received single agent azacitidine, 73 (48%) single agent decitabine, and 43 (29%) combinations. With a median follow‐up of 17 months, overall response rate (ORR) was 75%, with 41% achieving complete response (CR). Median overall survival (OS) was 24 months (95%CI: 20‐28) and event‐free survival 14 months (95%CI: 11‐17). By multivariate analysis, age < 70 years, higher levels of hemoglobin, absence of blast in peripheral blood and lower CPSS cytogenetic risk predicted for better OS. CR was significantly higher in those patients treated with decitabine (58.3%) when compared with azacitidine (20.6%) (P < .001). 13 patients (9%) received allo‐SCT after a median of 4 cycles of HMA. 66 patients (50%) had HMA failure: 26 primary (34%) and 50 secondary (66%), including 35 (46%) that transformed to AML. Outcomes after HMA failure were poor with OS of 7 months (95%CI: 3‐12). In conclusion, HMA are effective in CMML but new agents and combinations are needed. This data could be a benchmark for further drug development in CMML.

31 October 2016 in Leukemia
Verified
Journal Article
Closed access
GMG Montalban-Bravo
G Montalban-Bravo
XHX Huang
X Huang
EJE Jabbour
E Jabbour
GBG Borthakur
G Borthakur
CDC D DiNardo
C D DiNardo
GGG Garcia-Manero
G Garcia-Manero

24 April 2013 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
AAAna Alfonso Alfonso-Piérola
Ana Alfonso Alfonso-Piérola
MRMargarita Redondo
Margarita Redondo
TRTomás Rubio
Tomás Rubio
BOBeatriz Del Olmo
Beatriz Del Olmo
PRPablo Rodríguez‐Wilhelmi
Pablo Rodríguez‐Wilhelmi
RLRamón Lecumberri
Ramón Lecumberri
Extensive screening strategies to detect occult cancer in patients with unprovoked venous thromboembolism (VTE) are complex and no benefit in terms of survival has been reported. FDG‐PET/CT (2‐[F‐18] fluoro‐2‐deoxy‐D‐glucose positron emission tomography combined with computed tomography), a noninvasive technique for the diagnosis and staging of malignancies, could be useful in this setting. Consecutive patients ≥ 50 years with a first unprovoked VTE episode were prospectively included. Screening with FDG‐PET/CT was performed 3–4 weeks after the index event. If positive, appropriate diagnostic work‐up was programmed. Clinical follow‐up continued for 2 years. Blood samples were collected to assess coagulation biomarkers. FDG‐PET/CT was negative in 68/99 patients (68.7%), while suspicious FDG uptake was detected in 31/99 patients (31.3%). Additional diagnostic work‐up confirmed a malignancy in 7/31 patients (22.6%), with six of them at early stage. During follow‐up, two patients with negative FDG‐PET/CT were diagnosed with cancer. Sensitivity (S), positive (PPV) and negative predictive values (NPV) of FDG‐PET/CT as single tool for the detection of occult malignancy were 77.8% (95% CI: 0.51–1), 22.6% (95% CI: 0.08–0.37) and 97.1% (95% CI: 0.93–1), respectively. Median tissue factor (TF) activity in patients with occult cancer was 5.38 pM vs. 2.40 pM in those without cancer (p = 0.03). Limitation of FDG‐PET/CT screening to patients with TF activity > 2.8 pM would improve the PPV to 37.5% and reduce the costs of a single cancer diagnosis from 20,711€ to 11,670€. FDG‐PET/CT is feasible for the screening of occult cancer in patients with unprovoked VTE, showing high S and NPV. The addition of TF activity determination may be useful for patient selection.

23 October 2024 in Blood Advances
Verified
Journal Article
Open access
MPMaria Luisa Palacios-Berraquero
Maria Luisa Palacios-Berraquero
PRPaula Rodriguez-Marquez
Paula Rodriguez-Marquez
MCMaria Erendira Calleja-Cervantes
Maria Erendira Calleja-Cervantes
NBNerea Berastegui
Nerea Berastegui
AZAintzane Zabaleta
Aintzane Zabaleta
FPFelipe Prosper
Felipe Prosper
Hematologic toxicity is a common side effect of chimeric antigen receptor T-cell (CAR-T) therapies, being particularly severe among patients with relapsed or refractory multiple myeloma (MM). In this study, we characterized 48 patients treated with B-cell maturation antigen (BCMA) CAR-T cells to understand kinetics of cytopenia, identify predictive factors, and determine potential mechanisms underlying these toxicities. We observed that overall incidence of cytopenia was 95.7%, and grade >3 thrombocytopenia and neutropenia, 1 month after infusion, was observed in 57% and 53% of the patients, respectively, being still present after 1 year in 4 and 3 patients, respectively. Baseline cytopenia and high peak inflammatory markers were highly correlated with cytopenia that persisted up to 3 months. To determine potential mechanisms underlying cytopenias, we evaluated the paracrine effect of BCMA CAR-T cells on hematopoietic stem and progenitor cell (HSPC) differentiation using an ex vivo myeloid differentiation model. Phenotypic analysis showed that supernatants from activated CAR-T cells (spCAR) halted HSPC differentiation, promoting more immature phenotypes, which could be prevented with a combination of interferon γ, tumor necrosis factor α/β, transforming growth factor β, interleukin-6 (IL-6) and IL-17 inhibitors. Single-cell RNA sequencing demonstrated upregulation of transcription factors associated with early stages of hematopoietic differentiation in the presence of spCAR (GATA2, RUNX1, CEBPA) and a decrease in the activity of key regulons involved in neutrophil and monocytic maturation (ID2 and MAFB). These results suggest that CAR-T activation induces HSPC maturation arrest through paracrine effects and provides potential treatments to mitigate the severity of this toxicity.